United States Continuous Glucose Monitoring Market Forecast 2025-2033

United States Continuous Glucose Monitoring Market Size & Forecast 2025-2033

The United States Continuous Glucose Monitoring (CGM) Market is expected to grow from US$ 2.05 billion in 2024 to US$ 4.23 billion by 2033 at a CAGR of 8.36% for the 2025-2033 forecast period. This is fueled by increasing prevalence of diabetes, advances in technology, heightened awareness, and expanding insurance coverages, making CGM systems an integral tool for contemporary diabetes care.

United States Continuous Glucose Monitoring Market Overview

Continuous Glucose Monitoring (CGM) is a newer technology that monitors blood glucose levels in real time, providing a dynamic picture of the fluctuations of glucose levels throughout the day and night. CGM devices differ from the conventional finger-stick method in that they contain a tiny sensor inserted beneath the skin that continuously measures interstitial glucose levels, typically downloading data to a smartphone or wearable device.

In the United States, CGM has become immensely popular as a result of increasing diabetes prevalence, particularly in both Type 1 and insulin-requiring Type 2 patients. Major players such as Dexcom, Abbott (FreeStyle Libre), and Medtronic have advanced CGM, making it more user-friendly and accurate, and insurance reimbursement has widened to include Medicare reimbursement, further increasing adoption. Doctors increasingly advise CGM for tighter glycemic control and fewer complications. In addition, tech-friendly patients are drawn to CGM's remote monitoring, real-time alerts, and digital integration. The increasing demand is a clear indication of a nationwide shift toward proactive, data-driven diabetes management.

United States Continuous Glucose Monitoring Market Growth Drivers

Rising Prevalence and Earlier Diagnosis of Diabetes

The rising incidence of diabetes in the U.S.-with more than 38 million Americans affected-is continuing to drive demand for continuous glucose monitoring systems. An increasing emphasis on early intervention and stringent glycemic control is leading both clinicians and patients to embrace CGM instead of conventional techniques. Especially among Type 1 diabetes patients and insulin-dependent Type 2 patients, CGM minimizes long-term complications as well as hospitalization. Campaigns to create awareness among the public, screening programs, and preventive healthcare schemes have led to early intervention becoming a top priority, increasing CGM usage among all age groups.

Technological Innovation and Wearable Integration

Improvements in CGM technology such as factory-calibrated sensors, extended wear times, smartphone connectivity, and real-time alerts have greatly enhanced usability and accuracy. Leaders among these companies are Dexcom and Abbott, which have combined CGM with insulin pumps and mobile health platforms. These technologies enable data-driven treatment changes and remote patient monitoring, enhancing the appeal of CGM among clinicians and patients alike. The move towards health-tech wearables in the United States has gone a long way in popularizing the use of CGMs, particularly among healthy and tech-savvy consumers. June 2024, Abbott gained FDA approval for two new over-the-counter continuous glucose monitoring systems - Lingo(TM) and Libre Rio(TM).

Increasing Insurance Coverage and Government Support

Higher reimbursement under Medicare, Medicaid, and commercial payers has brought CGM into broader reach, particularly for older adults and lower-income individuals. CMS also covers CGMs for a wider group of patients who are on basal insulin. This has eliminated major cost barriers that would otherwise limit adoption. Federal support of digital health and remote monitoring after COVID-19 has also facilitated CGM integration into everyday care. Policy changes that encourage telehealth and distance disease management further enhance the significance of CGM as a fundamental element in long-term diabetes management.

Challenges in United States Continuous Glucose Monitoring Market

High Upfront and Recurring Costs

Despite increasing reimbursement coverage, CGM systems are still out of reach for many underinsured or uninsured populations. The upfront cost of devices like the Dexcom G7 or Abbott FreeStyle Libre 3, along with ongoing sensor replacement fees, can discourage long-term utilization. Even in insured patients, substantial deductibles and co-pays can constrain uptake. Absent additional price competition or government subsidy extension, affordability will continue to be an important barrier to serving underserved communities.

User Compliance and Data Overload

Whereas CGMs offer continuous information, not everybody understands how to use it or react to trend alarms. Some patients are overwhelmed by real-time reminders or suffer from alarm fatigue. Skin redness, sensor removal, and the need to calibrate can be sources of frustration as well. Elderly or less technologically advanced users tend to be non-adherent specifically due to difficulty in dealing with digital health devices. Better education of users and ease of device use will be critical in overcoming this barrier.

United States Continuous Glucose Monitoring Sensors Market

CGM sensors are the underlying technology that performs glucose detection under the skin. As biocompatibility and sensor lifetime have improved to 14 days, the market has witnessed robust growth in demand. The space is dominated by players such as Dexcom and Abbott with factory-calibrated, throwaway sensors that improve patient comfort and precision. As adoption grows, sensors become smaller, more robust, and compatible with insulin pumps and mobile apps. Advances in sensor technology continue to propel market growth, particularly in the outpatient and homecare arenas.

United States Continuous Glucose Monitoring Transmitters Market

Transmitters transmit data from the sensor to a mobile app, receiver, or insulin pump. The segment is transitioning to real-time Bluetooth devices with improved battery life and wireless communication. Next-generation transmitters are reusable and accommodate long-term connectivity, which means that in the long run, they are cost-effective. With interoperability as a selling point, they are suitable for integration with telehealth platforms and closed-loop insulin delivery systems. Transmitters also contribute to customized health data analysis, promoting patient engagement and physician decision-making.

United States Continuous Glucose Monitoring Hospitals Market

Hospitals are implementing CGMs in in-patient diabetes care and post-operative care to prevent glycemic events. With real-time monitoring and alerts, CGMs can minimize acute complications such as hypoglycemia and hyperglycemia during hospitalization. CGMs also facilitate critical care in emergency and intensive care units. Increased hospital protocol acceptance of CGMs is an indicator of their utility in streamlining nurse workload, enhancing patient outcomes, and facilitating remote glucose monitoring-especially useful during the COVID-19 pandemic.

California Continuous Glucose Monitoring Market

California, which is home to numerous top med-tech firms, is the central hub for CGM innovation and uptake. With diabetes prevalence at high levels and solid health tech infrastructure, the state has taken to CGMs in hospitals, clinics, and homecare. Tech-friendly consumers, solid insurance support, and active digital health startups fuel market uptake. Friendly public health promotion and collaborations among private industry and research centers continue to open access statewide.

New York Continuous Glucose Monitoring Market

New York's large, heterogeneous population and sophisticated healthcare system drive swift CGM adoption. Hospitals and outpatient facilities increasingly integrate CGM into diabetes treatment pathways. Public health programs, particularly in low-income communities, prioritize early detection of diabetes and digital health integration. An expanding number of telemedicine providers and endocrinologists providing CGM-based care facilitates the segment's continued growth in urban and suburban settings.

New Jersey Continuous Glucose Monitoring Market

New Jersey, having the highest density of healthcare centers and pharma firms, exhibits excellent growth in the deployment of CGMs. Spiking diabetes and growing the need for remote monitoring solutions have established CGMs as a vital component of managing chronic conditions. Hospitals, private clinics, and retail pharmacies are making efforts to increase the availability of CGMs, complemented by positive insurance pay and patient education initiatives designed to enhance health outcomes.

Washington Continuous Glucose Monitoring Market

Washington State enjoys robust healthcare infrastructure and priorities placed on digital health solutions, so it is a leading CGM market. Integration of technology within healthcare systems and cross-industry engagement between research universities and biotech firms drive adoption and innovation. Initiatives for healthcare disparities reduction have also helped ensure CGM access for rural and minority groups. Public health priority on chronic disease management and tech-driven delivery of care in Washington State enhances long-term CGM growth.

Market Segmentation

Component

• Sensors
• Transmitters
• Receivers

End User

• Hospitals
• Homecare Settings
• Others

Top 10 States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• Washington
• New Jersey
• Rest of United States

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Abbott Laboratories
• Roche
• Tandem Diabetes Care
• DexCom Inc.
• Senseonics Holdings, Inc.
• Ypsomed Holding AG
• Medtronic Plc.
• i-Sens Inc.